Medical technology

How the NHS can improve medtech adoption

Just 15% of NHS managers and clinicians describe their organisation as an early adopter of new medical technologies. Achieving wider adoption depends on stronger local evidence, better-designed pilots, a more realistic approach to implementation, and closer collaboration between suppliers, providers and systems.

Politicians rarely miss an opportunity to talk up the power of innovation in healthcare.

At its birth, Nye Bevan famously spoke of an NHS that must be “always changing, growing and improving” – and nearly eight decades later, the 10-Year Health Plan reiterated that message by putting technology at the heart of its ambitions for reform.

Yet turning political aspirations into the practical adoption of new medical technologies at scale has proved much harder. Research conducted earlier this year by Uniphar Medtech and the National Health Executive underlines the point.

Just 15% of NHS managers and clinicians in our survey described their organisation as an “early adopter” of new technology, with most describing themselves as “cautious” (27%) or “selective” (37%) in their approach.

Many respondents pointed to familiar barriers:

  • Capacity and implementation issues – even technologies that promise efficiencies can create significant upfront work for organisations already facing workforce pressures.
  • The evidence gap – NHS organisations want clear evidence that technologies work in practice, yet suppliers often need sustained adoption to generate that data.
  • Changing definitions of value – the benefits of medtech increasingly need to be demonstrated across whole pathways, making it harder to establish where costs sit, where benefits accrue and how investment should be justified.
  • Financial pressures – many innovations require upfront investment while benefits may take years to materialise, creating risks that can be difficult to absorb.

So what can suppliers, commissioners and provider leaders do to overcome these obstacles and make promising technologies easier to adopt and scale?

Four priorities emerged from our findings.

1. Bring the right people into the decision early

Although clinical support is vital, our research highlighted that successful adoption increasingly depended upon engaging a much wider set of decision makers, sometimes spanning different NHS organisations.

For suppliers, early engagement is essential to understand how a technology fits with local priorities, existing pathways, budget constraints and implementation realities before the proposition is too far developed.

As well as helping to build a credible business case, this process can help to surface potential barriers earlier and avoid situations where clinical enthusiasm is undermined later by operational or financial concerns – as several respondents mentioned in our research.

On the NHS side, there also needs to be a clear mechanism for bringing those perspectives together so that technologies are assessed against a common set of priorities rather than through a series of disconnected conversations.

Multidisciplinary assessment groups, value-analysis processes and consistent evaluation frameworks can all help organisations assess innovation more systematically while retaining flexibility around local priorities and pressures.

2. Start with the problem, then build the evidence

Most medtech companies recognise that generic claims about efficiency, productivity or better outcomes rarely make a compelling local business case.

However, as one respondent put it, “the informed adoption of technologies driven by identified clinical need and evidence-based practice is … rarer.”

The strongest business cases address a specific local pressure and use local data where possible to show the likely clinical, operational and financial impact.

This means evidence generation needs to start early in the planning process.

Identifying clinical leaders and centres with the expertise and appetite to lead evidence development can help ensure evaluations are designed around questions that truly matter to the NHS.

Health Innovation Networks can also help new entrants design evaluations, access suitable NHS settings and generate real-world evidence on clinical outcomes and practical benefits such as patient flow, staff time, pathway capacity and implementation costs.

3. Define success around delivering long-term value

Another challenge is ensuring that evaluation is designed around the full value a technology is expected to deliver, rather than simply whether it works in a particular setting.

Before the first patient enters a pilot, there should be agreement on the outcomes that matter, who will make the final decision and – crucially – where recurrent funding could come from.

This agreement should include clear clinical and health-economic endpoints.

New technologies may carry a higher unit price but generate savings elsewhere in the system. If those wider benefits form part of the case for adoption, the measures used to demonstrate them need to be agreed upfront.

A stronger focus on value-based healthcare also carries implications for procurement and commercial models, allowing technologies to be assessed against their impact on outcomes, pathway efficiency and use of NHS resources, rather than primarily on unit cost.

Where those measures are clear and measurable, there is scope to explore risk-sharing agreements that link part of the commercial arrangement to agreed outcomes – reducing the NHS’s financial exposure if the expected benefits do not materialise.

4. Build partnerships around implementation

Even where the case for a technology is strong, embedding it into routine practice can place significant demands on already stretched teams.

Workforce pressures were cited by 41% of respondents as a challenge to medtech adoption, while 29% pointed to broader capacity constraints.

Commissioners and provider leaders need a realistic view of the time and resource required to redesign workflows, integrate systems, train staff and manage change.

Suppliers can help reduce that burden through practical implementation support, including project management, training and technical expertise – which many companies are now building into their value proposition.

There is also opportunity for trusts to learn more systematically from each other's experience.

If one trust has already worked through the pathway redesign, clinical governance and training needed to introduce a technology, others should be able to build on that experience rather than starting from scratch.

We believe there is a strong case for building a central repository of evaluations, implementation plans and outcome frameworks that would help trusts see what has already been tried, what worked and what could be replicated.

Innovation will always depend on organisations willing to go first. But with only 15% of organisations seeing themselves as early adopters, we need to ensure their experience helps others to follow in their wake.

Above all, this requires greater collaboration between suppliers, providers and systems – and better ways of sharing the hard-earned lessons of adoption.

To learn more about how Uniphar Medtech is supporting healthcare providers and partners across the sector, visit Uniphar Medtech Contact.

mag

NHE Issue 109

Sparking innovation across healthcare and research

Click below to read more!

More articles...

View all
Online conferences

Presenting

2025 Online Conferences

In partnership with our community of health sector leaders responsible for delivering the UK's health strategy across the NHS and the wider health sector, we’ve devised a collaborative calendar of conferences and events for industry leaders to listen, learn and collaborate through engaging and immersive conversation. 

All our conferences are CPD accredited, which means you can gain points to advance your career by attending our online conferences. Also, the contents are available on demand so you can re-watch at your convenience.

National Health Executive Podcast

Listen to industry leaders on everything within healthcare

Whether it's the latest advancements in medical technology, healthcare policies, patient care innovations, or the challenges facing healthcare providers, we cover it all.

 

Join us as we engage with top healthcare professionals, industry leaders, and policy experts to bring you insightful conversations that matter.